WO2002014348B1 - Glycoproteins and methods of use thereof - Google Patents
Glycoproteins and methods of use thereofInfo
- Publication number
- WO2002014348B1 WO2002014348B1 PCT/US2001/025240 US0125240W WO0214348B1 WO 2002014348 B1 WO2002014348 B1 WO 2002014348B1 US 0125240 W US0125240 W US 0125240W WO 0214348 B1 WO0214348 B1 WO 0214348B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- therapeutic
- seq
- administering
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Abstract
The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.
Claims
AMENDED CLAIMS
[Received by the International Bureau on 30 September 2002 (30.09.2002); new claims 41-48 added (2 pages)]
39. A method for determining the presence of or predisposition to a reproductive disorder in a subject, the method comprising: a) measuring the amount of a ARP/ BRP nucleic acid in a sample from the mammalian subject; and b) comparing the amount of said nucleic acid in step (a) to the amount of the nucleic acid present in a control sample, wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates a disease condition.
40. A method for expressing an ARP/BRP polyppetide as a product if an endogenous gene in a cell, wherein the polypeptide is expressed at a modified level in a comparison to the wild type cell, the method comprising;
(a) transfecting the cell with a DNA constuct, the DNA constrict comprising a transcription regulatory element in operative connection to the endogenous gene, thereby producing a recombinant cell and/or
(b) transfecting the cell with a DNA constuct, the DNA constrict comprising a amplifiable gene and a DNA targeting sequence capable of inserting the amplifiable gene in operative connection to the endogenous gene, thereby producing a recombinant cell a
(c) culruring the recombinant cell, and if desired, selecting cells containing multiple copies of the endogenous gene.
41. A method of treating or preventing hypothyroidism in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a protein multimer of claim 17 or 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said hypothyroidism in said subject.
42. A method of modulating thyroid hormone production in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a protein multimer of claim 17 or 18 wherein said therapeutic is administered in an amount sufficient to modulate thyroid production in said subject.
43. A method of treating or preventing a thyroid related disorder in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a protein no
multimer of claim 17 or 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said thyroid related disorder in said subject.
44. A method of treating or preventing a pituitary related disorder in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a protein multimer of claim 17 or 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said pituitary related disorder in said subject.
45. A method of treating or preventing hypothyroidism in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said hypothyroidism in said subject.
46. A method of modulating thyroid hormone production in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 18 wherein said therapeutic is administered in an amount sufficient to modulate thyroid production in said subject.
47. A method of treating or preventing a thyroid related disorder in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said thyroid related disorder in said subject.
48. A method of treating or preventing a pituitary related disorder in a subject, the method comprising administering to a subject in need thereof a therapeutic comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 18 wherein said therapeutic is administered in an amount sufficient to treat or prevent said pituitary related disorder in said subject.
Ill
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01962112A EP1330469A2 (en) | 2000-08-11 | 2001-08-10 | Glycoproteins and methods of use therefof |
| IL15429701A IL154297A0 (en) | 2000-08-11 | 2001-08-10 | Glycoproteins, their preparation and use |
| AU2001283319A AU2001283319A1 (en) | 2000-08-11 | 2001-08-10 | Glycoproteins and methods of use thereof |
| JP2002519485A JP2004527214A (en) | 2000-08-11 | 2001-08-10 | Novel glycoproteins and methods of their use |
| CA002417141A CA2417141A1 (en) | 2000-08-11 | 2001-08-10 | Novel glycoproteins and methods of use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22503500P | 2000-08-11 | 2000-08-11 | |
| US60/225,035 | 2000-08-11 | ||
| US85146501A | 2001-05-08 | 2001-05-08 | |
| US09/851,465 | 2001-05-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2002014348A2 WO2002014348A2 (en) | 2002-02-21 |
| WO2002014348A3 WO2002014348A3 (en) | 2003-05-15 |
| WO2002014348B1 true WO2002014348B1 (en) | 2003-11-13 |
Family
ID=26919244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/025240 WO2002014348A2 (en) | 2000-08-11 | 2001-08-10 | Glycoproteins and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1330469A2 (en) |
| JP (1) | JP2004527214A (en) |
| AU (1) | AU2001283319A1 (en) |
| CA (1) | CA2417141A1 (en) |
| IL (1) | IL154297A0 (en) |
| WO (1) | WO2002014348A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513865A4 (en) | 2002-05-28 | 2006-05-03 | Univ Minnesota | Crisp polypeptides as contraceptives and inhibitors of sperm capacitation |
| WO2003104807A1 (en) * | 2002-06-10 | 2003-12-18 | Zymogenetics, Inc. | Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action |
| WO2005058953A2 (en) * | 2003-12-12 | 2005-06-30 | Regeneron Pharmaceuticals, Inc. | Ogh fusion polypeptides and therapeutic uses thereof |
| CN116676324B (en) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | System and method for constructing and releasing anti-tumor effector protein based on Kil protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508261A (en) * | 1991-06-18 | 1996-04-16 | University Of Medicine & Dentistry Of New Jersey | Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same |
| KR960704932A (en) * | 1994-08-12 | 1996-10-09 | 에이치. 에스. 리헤이 | SINGLE-CHAIN FORMS OF THE GLYCOPROTEIN HORMONE QUARTET |
| US6635256B1 (en) * | 1998-10-19 | 2003-10-21 | Washington University | Glycoprotein hormone compositions comprising two β subunits and methods of use thereof |
| EP1053324B1 (en) * | 1998-02-13 | 2006-08-16 | ZymoGenetics, Inc. | Novel cystine knot protein and materials and methods for making it |
| US20020068279A1 (en) * | 1999-12-06 | 2002-06-06 | Curagen Corporation | Novel Proteins and nucleic acids encoding the same |
| US20030143695A1 (en) * | 1999-12-17 | 2003-07-31 | Shuji Hinuma | Novel polypeptide and dna thereof |
| US20030059877A1 (en) * | 2000-01-18 | 2003-03-27 | Sietse Mosselman | Human cystine knot polypeptide |
| AU2001239765A1 (en) * | 2000-02-14 | 2001-08-27 | Smith Kline Beecham Corporation | Novel compounds |
| US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| AU2001261370A1 (en) * | 2000-05-08 | 2001-11-20 | Serono, Inc. | Nucleic acids encoding polypeptides related to the alpha subunit of the glycoprotein hormone family and methods of use thereof |
| WO2002030978A1 (en) * | 2000-10-06 | 2002-04-18 | Regeneron Pharmaceuticals, Inc. | Polypeptides, methods of making, and uses thereof |
-
2001
- 2001-08-10 JP JP2002519485A patent/JP2004527214A/en active Pending
- 2001-08-10 IL IL15429701A patent/IL154297A0/en unknown
- 2001-08-10 AU AU2001283319A patent/AU2001283319A1/en not_active Abandoned
- 2001-08-10 CA CA002417141A patent/CA2417141A1/en not_active Abandoned
- 2001-08-10 WO PCT/US2001/025240 patent/WO2002014348A2/en active Application Filing
- 2001-08-10 EP EP01962112A patent/EP1330469A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1330469A2 (en) | 2003-07-30 |
| WO2002014348A3 (en) | 2003-05-15 |
| CA2417141A1 (en) | 2002-02-21 |
| IL154297A0 (en) | 2003-09-17 |
| AU2001283319A1 (en) | 2002-02-25 |
| JP2004527214A (en) | 2004-09-09 |
| WO2002014348A2 (en) | 2002-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sauer et al. | DNA template and activator-coactivator requirements for transcriptional synergism by Drosophila bicoid | |
| McBride et al. | The carboxy‐terminal domain shared by the bovine papillomavirus E2 transactivator and repressor proteins contains a specific DNA binding activity. | |
| Gostissa et al. | Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1 | |
| Lück-Vielmetter et al. | Replacement of threonine residues by serine and alanine in a phosphorylatable heavy chain fragment of Dictyostelium myosin II | |
| Tjian | The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes | |
| CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
| CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| Shibata et al. | Fibroblast growth‐stimulating activity of S100A9 (MRP‐14) | |
| CA2302808A1 (en) | 50 human secreted proteins | |
| Xu et al. | Mutually exclusive interactions of EHD1 with GS32 and syndapin II | |
| EP1284297A3 (en) | Identification and use of molecules implicated in pain | |
| JP2004500807A (en) | Screening method for candidate drugs | |
| WO2002014348B1 (en) | Glycoproteins and methods of use thereof | |
| EP1279744A3 (en) | Identification and use of molecules implicated in pain | |
| AU8649698A (en) | Cell cycle-regulating proteins | |
| Liu et al. | Mutations of the serine phosphorylated in the protein phosphatase-1-binding motif in the skeletal muscle glycogen-targeting subunit | |
| Atanasoski et al. | Isolation of the human genomic brain-2/N-Oct 3 gene (POUF3) and assignment to chromosome 6q16 | |
| US7070940B2 (en) | Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein | |
| Mori et al. | Identification of brain-specific splicing variants of the hDLG1 gene and altered splicing in neuroblastoma cell lines | |
| US20060094101A1 (en) | Mk2 interacting proteins | |
| Maeda et al. | A novel nucleolar protein interacts with ribosomal protein S19 | |
| WO2001076457B1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
| WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
| WO2003057827A3 (en) | Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2001283319 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2417141 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 154297 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002519485 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001962112 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001962112 Country of ref document: EP |
|
| B | Later publication of amended claims |
Free format text: 20020930 |